Advances in the mechanism of aging-driven metabolic associated fatty liver disease and related targeted therapeutic strategies
- VernacularTitle:衰老驱动代谢相关脂肪性肝病的机制及靶向治疗策略研究进展
- Author:
Rui CHEN
1
;
Lungen LU
1
Author Information
- Publication Type:Review
- Keywords: Non-alcoholic Fatty Liver Disease; Cellular Senescence; Aging; Lipid Metabolism Disorders; Insulin Resistance; Inflammation
- From: Journal of Clinical Hepatology 2025;41(6):1174-1180
- CountryChina
- Language:Chinese
- Abstract: Metabolic associated fatty liver disease （MAFLD） is a liver disease associated with metabolic disorders， and it is characterized by excessive fat deposition in hepatocytes and is closely associated with insulin resistance and genetic susceptibility. Aging is an important factor in the progression of MAFLD and is positively correlated with the mortality rate of patients with MAFLD. The pathophysiological mechanisms of MAFLD involve lipid metabolism disorders， insulin resistance， inflammation， and oxidative stress， and aging exacerbates the pathological process of MAFLD by further affecting these key mechanisms. Cell senescence is an important factor in organismal aging， and therapeutic strategies targeting senescent cells can reduce the number of senescent cells or inhibit the inflammatory factors secreted by such cells， thereby helping to slow down the progression of MAFLD. In addition， the screening of novel regulatory factors provides new targets for the development of new drugs for MAFLD treatment. Although several anti-aging therapies have entered clinical trials， further studies are needed to validate the specificity and potential liver damage of these therapies due to the complex mechanisms of aging on the liver. Transforming multisystem metabolic dysfunction therapies for MAFLD into specialized therapies for aging may provide new ideas for MAFLD drug development.
